Pacific Biosciences Sequel II Systems Deployed to Scale-Up Global Viral Surveillance Initiatives Focused on COVID-19 - Seite 2
“Early in the pandemic, we partnered with PacBio to sequence COVID-19 samples and expand our understanding of how the virus is evolving,” said Dr. Marcia Eisenberg, Chief Scientific Officer, Labcorp Diagnostics. “We are pleased to work with the CDC to sequence an increasing number of samples as part of our ongoing, all-in fight against COVID-19.”
The PacBio HiFiViral for SARS-CoV-2 Workflow protocol is publicly available and can be accessed at: www.pacb.com/COVID-19. This scalable protocol, which enables sequencing the complete SARS-CoV-2 viral genome in batch sizes ranging from 96 to 900 samples per SMRT Cell, allows any laboratory to rapidly and efficiently power viral mutation surveillance using PacBio’s HiFi sequencing.
1. South Carolina Department of Health and Environmental Control. South Carolina Public Health Officials Detect Nation’s First Known Cases of the COVID-19 Variant Originally Detected in South Africa. (January 28, 2021). Retrieved from: https://scdhec.gov/index.php/news-releases/south-carolina-public-healt ....
2. WTVR-TV. First case of South African COVID variant detected in Virginia. (February 5, 2021). Retrieved from: https://www.wtvr.com/news/coronavirus/south-african-covid-variant-dete ...
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on Single Molecule,
Real-Time (SMRT) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism.
Cited in thousands of peer-reviewed publications, PacBio sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and
microbiology. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to market leadership, uses, accuracy, presentations
regarding, quality or performance of, or benefits of using, our products or technologies, including SMRT technology, the suitability or utility of our methods, products or technologies for
particular applications or projects, including in connection with SARS-CoV-2 surveillance and the detection of mutations and variants thereof, the ability of the Company to be successful in
reaching its technological and commercial potential, and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks,
uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information
expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the
Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Pacific Biosciences
undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.